Autogen to get milestone payment from Merck
13 February, 2003 by Melissa TrudingerMelbourne-based biotech Autogen will receive $AUD1.39 million in a milestone payment from commercial partner Merck, the company announced today.
Gardiner Foundation announces R&D funding awards
12 February, 2003 by Melissa TrudingerThe Geoffrey Gardiner Dairy Foundation has announced the inaugural recipients of its major research and development funding initiative.
GroPep says turn-around is on track despite loss
12 February, 2003 by Melissa TrudingerDespite slightly lower than expected revenues for the half-year ending December 31, Adelaide company GroPep was on track for full recovery, said CFO Tony Mitchell today.
New target found in search for Alzheimer's treatment
12 February, 2003 by Graeme O'NeillResearchers hunting the serial murderer responsible for the progressive, mass-death of neurons in Alzheimer's disease, the most common form of dementia, have found a new suspect.
Mad cow just got madder in face of multifaceted molecule
11 February, 2003 by Graeme O'NeillThe story of the so-called prion diseases, including 'mad cow' disease, is one of the strangest in the annals of 20th century medical science -- and it grows stranger still.
Bionomics, JJR arrangement has happy ending
10 February, 2003 by Melissa TrudingerA collaboration between Adelaide company Bionomics and Johnson and Johnson Research (JJR) has been concluded without an ongoing commercial arrangement.
Domantis granted patent, rights on new antibody selection technique
10 February, 2003 by Graeme O'NeillUK-based Domantis, a developer of single-domain antibody therapeutics, has been granted a US patent on a new emulsion technique for selecting antibodies and antibody fragment.
VRI BioMedical names new CEO
07 February, 2003 by Iain ScottPerth-based probiotics and diagnostics company VRI BioMedical has named Dr Peter French as its new CEO.
Our first cloned sheep found dead
07 February, 2003 by Melissa TrudingerMatilda, Australia's first cloned sheep, has died of unknown causes, according to the South Australian Research and Development Institute (SARDI).
Prima touts DCtag success in vaccine development
07 February, 2003 by Graeme O'NeillPrima BioMed subsidiary Panvax has reported that recent trials of its DCtag vaccine technology in sheep have confirmed its potential for developing novel vaccines and immunotherapies for human diseases including cancers, viral infections, malaria and tuberculosis.
Plant chloroplasts may leak GM transgenes
06 February, 2003 by Graeme O'NeillAn Adelaide University study has shown that confining transgenes to nature's own handy bottle, to prevent them escaping from genetically modified crops into non-GM crops or their weedy relatives, will not necessarily prevent transgenes escaping.
Gradipore announces tech success
06 February, 2003 by Melissa TrudingerSydney-based biotechnology company Gradipore (ASX: GDP) announced today that it had demonstrated removal of both infectious and non-infectious prion proteins from human biological samples using its proprietary Gradiflow technology.
New head for IMBcom
05 February, 2003 by Pete YoungThe commercialisation arm of Queensland's premier biotech research centre, the Institute for Molecular Bioscience, has capped a national search for a new chief executive by reaching into the Queensland bioscience community for its successful candidate.
PSL releases two electrophoresis systems
05 February, 2003 by Melissa TrudingerSydney company Proteome Systems has released two electrophoresis systems, the latest additions to its broad ProteomIQ platform for integrated high throughput proteomic analysis.
Chemeq brings in $10.6m for factory fund
04 February, 2003 by Graeme O'NeillPharmaceutical company Chemeq has completed a highly successful capital raising to fund construction of its $AUD25 million plant in Perth to manufacture its revolutionary antimicrobial polymer to suppress bacterial infections in livestock.
